Boehringer Ingelheim receives FDA approval for Senvelgo to treat diabetes in cat

Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus

Boehringer Ingelheim receives FDA approval for NexGard Plus

The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio

Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide shows nearly 19% weight loss in people with obesity

Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite

Boehringer Ingelheim begins clinical development for fibrotic diseases

‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,

Boehringer Ingelheim inaugurates largest European development centre for biotechnology

New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists

ProBioGen collaborates with Boehringer Ingelheim on DirectedLuck transposase technology

The new project further expands the partner's long-term collaboration on new technologies for R&D

Boehringer Ingelheim and Click Therapeutics expand collaboration to develop digital therapeutics for schizophrenia

Torrent enters into co-marketing partnership with Boehringer Ingelheim India

Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.

Boehringer Ingelheim InPedILD Phase III trial showed encouraging results for both primary endpoints

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

Lupin to acquire brands Ondero and Ondero - Met from Boehringer Ingelheim

The cash consideration for the above acquisition will be Euro 26 million.